Загрузка...
A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen()()
OBJECTIVES: To evaluate contraceptive effectiveness and safety of oral drospirenone 4 mg 24/4-day regimen in the United States. STUDY DESIGN: We performed a prospective, single-arm, multicenter phase 3 trial in sexually active women for up to thirteen 28-day treatment cycles. Primary outcome was the...
Сохранить в:
| Опубликовано в: : | Contracept X |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7286157/ https://ncbi.nlm.nih.gov/pubmed/32550535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conx.2020.100020 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|